Global cell therapy market is estimated to be valued at USD 2,583.8 Mn in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031). Global cell therapy market is expected to witness growth substantially over the next decade due to rising prevalence of chronic diseases coupled with increasing geriatric population globally. Cell therapy is an emerging and promising field that works with living cells to repair, replace or regenerate damaged tissues and cells. Advancements in cell culture techniques, associated technologies and regulatory approvals have supported the development of new therapies to treat blood disorders, cancers, autoimmune diseases and others. With significant investments in research and development and growing regulatory approvals, the cell therapy industry is poised to transform healthcare in the near future.

Market Dynamics:

Global cell therapy market growth is driven by factors such as rising prevalence of cancer and other chronic diseases, increase in funds for cell-based research, and advancement of technologies to develop novel therapies. Moreover, growing geriatric population worldwide prone to diseases is expected to boost demand. However, high costs associated with cell therapy development and stringent regulations for new therapies limits the market growth. Emerging economies offer lucrative opportunities for market players due to growing healthcare investments in countries like China, India and Brazil. Continuous research on stem cells and new applications of cell therapy are anticipated to create new avenues over the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global cell therapy market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cell therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Bristol Myers Squibb Company, Amgen Inc., Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Allogene Therapeutics, Athersys, Inc., Orchard Therapeutics, JW Therapeutics Co., Ltd., Dendreon Pharmaceuticals LLC., Autolus Therapeutics, APAC Biotech, CORESTEM, Inc., BioCardia, Inc., JCR Pharmaceuticals Co., Ltd., Oxford Biomedica, and CASI Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cell therapy market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell therapy market.

Detailed Segmentation-

• By Therapy Type:
  • Stem Cells
  • T-cells
  • Dendritic Cells
  • NK-cells
• By Indication:
  • Oncology
  • Cardiology
  • Neurology
  • Others
• By End User:
  • Hospitals
  • Clinics
  • Research Institutes
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bristol Myers Squibb Company
  • Amgen Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Allogene Therapeutics
  • Athersys, Inc.
  • Orchard Therapeutics
  • JW Therapeutics Co., Ltd.
  • Dendreon Pharmaceuticals LLC.
  • Autolus Therapeutics
  • APAC Biotech
  • CORESTEM, Inc.
  • BioCardia, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Oxford Biomedica
  • CASI Pharmaceuticals Inc.